Gohealth Inc (GOCO) Q4 2025 Earnings Call Transcript

Why It Matters

The results demonstrate AdaptHealth’s ability to strengthen its balance sheet and scale a transformative capitated model, positioning it for accelerated growth in a consolidating home‑medical‑equipment market.

Key Takeaways

• 2025 revenue $3.245B, marginally below prior year
• Adjusted EBITDA $616.7M, 19% margin, settlement impact
• Sleep and respiratory segments posted double‑digit growth
• Diabetes health revenue fell 7.4% after payer shift
• Largest industry capitated contract launched, targeting 10M patients

Pulse Analysis

AdaptHealth’s 2025 financials underscore a disciplined capital‑allocation strategy that blends modest organic growth with strategic portfolio reshaping. Net revenue reached $3.245 billion, while adjusted EBITDA held a healthy 19% margin despite a $14.5 million legal settlement and accelerated onboarding costs for a new capitated arrangement. A $128 million non‑cash goodwill impairment reflected a reassessment of the Diabetes Health segment, yet free cash flow surged to $219.4 million, enabling a $250 million debt paydown and earning upgrades from S&P and Moody’s. This balance‑sheet fortification equips the company to fund its ambitious growth initiatives.

Operationally, AdaptHealth recorded record patient censuses across sleep, respiratory, and wellness lines, driven by centralized order intake and AI‑powered pilots that trimmed order processing and patient‑phone times. Referral‑to‑setup intervals fell dramatically—sleep setup now averages nine days versus 23 a year ago—enhancing provider referrals and patient satisfaction. The launch of the largest capitated contract in home‑medical‑equipment history, initially covering 50,000 members with a roadmap to over 10 million, showcases the firm’s execution capability and creates a predictable revenue stream that offsets traditional fee‑for‑service volatility.

Looking ahead, the company projects 2026 revenue growth of 6%‑8% and organic expansion of up to 9.5%, anchored by the capitated contract’s ramp‑up and continued technology rollouts. A favorable CMS decision excluding core sleep and respiratory products from upcoming competitive bidding adds regulatory stability. While first‑quarter free‑cash‑flow is expected to dip due to front‑loaded contract costs, the long‑term outlook points to stronger margins, higher leverage control, and a competitive edge in a market where scale and integrated care models are increasingly decisive.